^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GZMB negative

    i
    Other names: GZMB, Granzyme B, T-Cell Serine Protease 1-3E, Cathepsin G-Like 1, Granzyme B (Granzyme 2, Cytotoxic T-Lymphocyte-Associated Serine Esterase 1), Cytotoxic T-Lymphocyte Proteinase 2, Cytotoxic Serine Protease B, Human Lymphocyte Protein, Fragmentin 2, CTSGL1, CTLA1, CSPB, CGL1, SECT, C11, HLP, Cytotoxic T-Lymphocyte-Associated Serine Esterase, Lymphocyte Protease, Fragmentin-2, Granzyme-2, Granzyme 2, CTLA-1, CGL-1, CSP-B, CCPI
    Entrez ID:
    3002
    Related biomarkers:
    Expression
    Mutation
    Others
    Associations

    News

    Trials
    1year
    Molecular and clinicopathological features of granzyme B-negative extranodal NK/T-cell lymphoma. (PubMed, Hum Pathol)
    In conclusion, GZMB expression is highly heterogeneous in ENKTLs and is associated with the activation of the JAK-STAT3 pathway and higher MYC expression. GZMB-negative ENKTLs correlate with an advanced clinical stage, suggesting the potential utility of GZMB immunohistochemistry as a biomarker of ENKTL.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • GZMB (Granzyme B) • PRF1 (Perforin 1) • TRG (T Cell Receptor Gamma Locus)
    |
    MYC expression • MYC positive • MYC negative • GZMB negative
    almost2years
    Transcriptional and Clinicopathological Implications of Granzyme B (GZMB)-negativity in Extranodal NK/T-cell lymphoma (USCAP 2023)
    GEP and IHC showed that GZMB expression is highly heterogeneous in ENKTLs and associated with activation of JAK-STAT3 signaling and higher MYC expression. GZMB-negative ENKTL has distinct GEP and advanced clinical stage, although not prognostically significant in our dataset. These findings imply that GZMB is a potential biomarker mirroring a certain molecular subtype of ENKTL.
    Clinical • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • GZMB (Granzyme B) • PRF1 (Perforin 1)
    |
    MYC expression • MYC negative • GZMB negative
    |
    nCounter® PanCancer Pathways Panel
    2years
    Granzyme B expression in tumor microenvironment as a biomarker for prognosis of triple-negative breast cancer (SABCS 2022)
    OS was significantly longer among patients with high GZMB expressing TNBC. These results may validate the significance of GZMB as a biomarker for various immunotherapies in TNBC.
    Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • CORIN (Corin, Serine Peptidase)
    |
    PD-L1 expression • TMB-H • GZMB negative